论文部分内容阅读
目的：探讨度洛西汀与米氮平治疗躯体形式障碍的临床疗效和安全性。方法将80例躯体形式障碍患者随机分为两组，每组40例，观察组口服度洛西汀治疗，对照组口服米氮平治疗，观察8周。采用汉密顿焦虑量表评定临床疗效，副反应量表评定不良反应。结果治疗后两组汉密顿焦虑量表总分均较治疗前呈持续性下降（P＜0．01），同期观察组较对照组下降更显著（P＜0．05或0．01）；治疗8周末观察组显效率为85．0％，对照组为62．5％，观察组显著高于对照组（χ2＝5．23，P＜0．05）。两组不良反应均较轻微，治疗各时点两组副反应量表评分比较差异无显著性（P＞0．05）。结论度洛西汀治疗躯体化障碍起效更快，疗效显著，安全性高，依从性好，优于米氮平治疗。“,”Objective To explore the efficacy and safety of duloxetine and mirtazapine in the treatment of somatoform disorder (SD) .Methods Eighty SD patients were randomly assigned to two groups of 40 ones each ,observation group took orally duloxetine and control did mirtazapine for 8 weeks .Efficacies were as‐sessed with Hamilton Anxiety Scale (HAMA) and adverse reactions with the Treatment Emergent Symp‐tom Scale (TESS) .Results After treatment the total scores of the HAMA of both groups lowered contin‐uously compared with pretreatment (P< 0 .01) ,in the corresponding period that lowered more significant‐ly in observation than in control group (P< 0 .05 or 0 .01) ;at the end of the 8th week obvious effective rate was significantly higher in observation than in control group (χ2 = 5 .23 ,P < 0 .05) .Adverse reactions of both groups were mild ,there were no significant group differences in the TESS scores at each time‐point . Conclusion Duloxetine takes effect more rapidly and has an evident effect ,higher safety and better com‐pliance compared with mirtazapine in the treatment of somatoform disorder .